Shukra Pharmaceuticals Ltd
PREFRENTIAL WARRANTS ALLOTMENT
FUNDRAISE
▲ Positive Development
LOW RISK
📅 Filed on BSE: 07 May 2026, 11:13 PM IST · BSE ID: d6b0bc4d-af1d-4345-90e2-66c6749b1ec4
View Original BSE Filing (PDF)
💡
In Simple Terms
The company issued 17.35 lakh new shares to its promoters, raising Rs. 4.42 Crore, and recommended a dividend.
🤖 AI Summary
- Board approved allotment of 1,735,000 equity shares to promoter warrant holders.
- Promoter entities Dakshesh Shah and Parshva Texchem India Private Limited converted warrants.
- Company received Rs. 4,42,42,500/- from the remaining exercise price of Rs. 25.50/- per warrant.
- Paid-up equity capital increased from Rs. 43,78,79,440/- to Rs. 43,96,14,440/-.
- Board recommended a final dividend of Rs. 0.01/- (1%) per equity share of Re 1/- each for FY2025-26.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Allotted
1,735,000
Amount Received from Warrant Exercise
Rs. 4,42,42,500/-
Post-Allotment Paid-up Equity Capital
Rs. 43,96,14,440/-
Final Dividend Recommended per Share
Rs. 0.01/-
Outstanding Warrants for Conversion
2,908,000
🏢 How This Affects the Company
The company's cash reserves increased by Rs. 4,42,42,500/- due to the receipt of warrant exercise price. The paid-up equity capital expanded from Rs. 43,78,79,440/- to Rs. 43,96,14,440/-.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take immediate action regarding the warrant conversion, but should monitor the upcoming Annual General Meeting for dividend approval.
👤
Who Is Affected
Existing shareholders will experience a minor dilution due to the issuance of 1,735,000 new equity shares, increasing the total shares outstanding to 43,96,14,440. Those holding shares on the record date will be eligible for the Rs. 0.01/- per share dividend if approved.
🔍
Management Signal
Management is utilizing a previously approved preferential warrant mechanism to raise capital from promoters and is recommending a dividend distribution to shareholders.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Annual General Meeting for approval of the recommended Rs. 0.01/- dividend.
Future filings regarding conversion of the remaining 2,908,000 outstanding warrants.
Details of how the raised capital of Rs. 4,42,42,500/- will be utilized by the company.
LOW RISK
The filing reports a fundraise and dividend, with no immediately apparent new risks.
💡 Investor Takeaway
Shukra Pharmaceuticals allotted 1,735,000 equity shares to promoters from warrant conversion, adding Rs. 4,42,42,500/- to company cash. The paid-up equity capital is now Rs. 43,96,14,440/-. A dividend of Rs. 0.01/- per share was recommended.
⚖️ Strengths & Concerns
✅ Positives
- Infusion of Rs. 4,42,42,500/- cash into the company from the conversion of preferential warrants by promoters.
- Board recommended a final dividend of Rs. 0.01/- (1%) per equity share for FY2025-26, subject to shareholder approval.
⚠️ Concerns
- 2,908,000 warrants remain outstanding for conversion, indicating potential future equity dilution if exercised.
- No prior filings or historical financial data were provided, limiting comparative analysis of the financial results.
📅 Company Track Record
No previous filings were found for Shukra Pharmaceuticals Ltd, limiting historical context for comparison of financial performance or operational trends. The company was incorporated in 1993 (CIN: L24231GJ1993PLC019079).
Based on publicly available historical data. For context only.